These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 39318358)

  • 1. Molecular mechanism of PARP inhibitor resistance.
    Huang Y; Chen S; Yao N; Lin S; Zhang J; Xu C; Wu C; Chen G; Zhou D
    Oncoscience; 2024; 11():69-91. PubMed ID: 39318358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    Nizialek E; Antonarakis ES
    Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    Faraoni I; Graziani G
    Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
    Herencia-Ropero A; Llop-Guevara A; Staniszewska AD; Domènech-Vivó J; García-Galea E; Moles-Fernández A; Pedretti F; Domènech H; Rodríguez O; Guzmán M; Arenas EJ; Verdaguer H; Calero-Nieto FJ; Talbot S; Tobalina L; Leo E; Lau A; Nuciforo P; Dienstmann R; Macarulla T; Arribas J; Díez O; Gutiérrez-Enríquez S; Forment JV; O'Connor MJ; Albertella M; Balmaña J; Serra V
    Genome Med; 2024 Aug; 16(1):107. PubMed ID: 39187844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
    Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
    Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    Washington CR; Moore KN
    Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
    Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
    Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
    J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    Luo L; Keyomarsi K
    Expert Opin Investig Drugs; 2022 Jun; 31(6):607-631. PubMed ID: 35435784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.
    Romeo M; Pardo JC; Martínez-Cardús A; Martínez-Balibrea E; Quiroga V; Martínez-Román S; Solé F; Margelí M; Mesía R
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches.
    Dilmac S; Ozpolat B
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.